{"id":"azithromycin-and-cefixime","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"2-8","effect":"Abdominal pain"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Rash"},{"rate":"1-3","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1541","moleculeType":"Small molecule","molecularWeight":"453.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin binds to the bacterial 50S ribosomal subunit to inhibit protein synthesis, while cefixime inhibits bacterial cell wall cross-linking by binding to penicillin-binding proteins. Together, they provide synergistic activity against a wide range of gram-positive and gram-negative bacteria, commonly used for respiratory and urogenital infections.","oneSentence":"This combination uses azithromycin (a macrolide antibiotic) and cefixime (a third-generation cephalosporin) to inhibit bacterial protein synthesis and cell wall synthesis, respectively, providing broad-spectrum coverage against multiple pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:10.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory tract infections (community-acquired pneumonia, bronchitis)"},{"name":"Urogenital infections (gonorrhea, chlamydia)"},{"name":"Mixed bacterial infections"}]},"trialDetails":[{"nctId":"NCT04349826","phase":"PHASE4","title":"The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2021-05-23","conditions":"Typhoid Fever","enrollment":2150},{"nctId":"NCT06468462","phase":"PHASE4","title":"Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-10-29","conditions":"Gonorrhea Male, Chlamydia (Male), Syphilis Male","enrollment":2900},{"nctId":"NCT06090565","phase":"PHASE4","title":"Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea","status":"COMPLETED","sponsor":"Bulovka Hospital","startDate":"2021-04-01","conditions":"Gonorrhea","enrollment":161},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01949363","phase":"PHASE1","title":"The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-12","conditions":"Gonorrhoea","enrollment":25},{"nctId":"NCT02830230","phase":"NA","title":"\"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs\"","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2016-07","conditions":"Cervical Inflammation and Human Papilloma Virus Performance","enrollment":508},{"nctId":"NCT01072136","phase":"PHASE3","title":"Empiric Therapy of Mucopurulent Cervicitis (MPC)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-03","conditions":"Vaginitis Bacterial, Cervicitis","enrollment":87},{"nctId":"NCT02224040","phase":"PHASE4","title":"Typhoid Fever: Combined vs. Single Antibiotic Therapy","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2013-08","conditions":"Typhoid Fever","enrollment":120},{"nctId":"NCT01720654","phase":"NA","title":"Expedited Partner Therapy for MSM in Peru","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-08","conditions":"Gonorrhea, Chlamydia","enrollment":165},{"nctId":"NCT01665690","phase":"PHASE4","title":"Washington State Community Expedited Partner Treatment (EPT) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2007-07","conditions":"Gonorrhea, Neisseria Gonorrhoeae, Chlamydia Trachomatis","enrollment":33222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":507,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"azithromycin and cefixime","genericName":"azithromycin and cefixime","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses azithromycin (a macrolide antibiotic) and cefixime (a third-generation cephalosporin) to inhibit bacterial protein synthesis and cell wall synthesis, respectively, providing broad-spectrum coverage against multiple pathogens. Used for Respiratory tract infections (community-acquired pneumonia, bronchitis), Urogenital infections (gonorrhea, chlamydia), Mixed bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}